Milagen

Milagen is a California-based biotechnology company specializing in the discovery and validation of novel biomarkers for oncology applications. The company utilizes a proprietary proteomics-based platform to identify cancer-specific proteins, which are then used to develop high-affinity monoclonal antibodies for diagnostic and therapeutic purposes. Milagen’s primary portfolio focuses on early-stage detection assays for breast, lung, and colorectal cancers, aiming to improve patient prognosis through early intervention. In addition to its clinical development programs, the company commercializes a range of research reagents and antibodies targeting heat shock proteins and other tumor markers. Milagen's approach integrates clinical proteomics with traditional hybridoma technology to bridge the gap between biomarker discovery and clinical utility.